Select a medication above to begin.
Sunosi
solriamfetol
Adult Dosing .
Dosage forms: TAB: 75 mg, 150 mg
narcolepsy
- [75-150 mg PO qam]
- Start: 75 mg PO qam, may incr. dose no more frequently than q3 days; Max: 150 mg/day; Info: for patients with excessive daytime sleepiness
excessive daytime sleepiness, obstructive sleep apnea-associated
- [37.5-150 mg PO qam]
- Start: 37.5 mg PO qam, may incr. dose no more frequently than q3 days; Max: 150 mg/day
renal dosing
- [see below]
- eGFR 30-59: start 37.5 mg qam x7 days, then may incr. to max 75 mg/day; eGFR 15-29: start 37.5 mg qam, max 37.5 mg/day; eGFR <15: avoid use
- HD/PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- MAO inhibitor use within 14 days
- eGFR <15
- cardiac disease, significant
- cardiac disease, unstable
- arrhythmia, severe
- caution: cardiovascular disease
- caution: cerebrovascular disease
- caution: HTN
- caution: elderly patients
- caution: eGFR 15-59
- caution: substance abuse history
- caution: bipolar disorder
- caution: psychosis history
Drug Interactions .
Overview
solriamfetol
dopamine-norepinephrine reuptake inhibitor
- dopaminergic effects (indirect)
- hypertensive effects
- tachycardia
- add MAO inhibitor to Interaction Check if recent (14 days) use
Contraindicated
Avoid/Use Alternative
Monitor/Modify Tx
Caution Advised
Adverse Reactions .
Serious Reactions
- abuse potential
Common Reactions
- headache
- nausea
- anorexia
- anxiety
- insomnia
- diarrhea
- xerostomia
- palpitations
- irritability
- constipation
- abdominal pain
- chest discomfort
- hyperhidrosis
- dizziness
- BP incr.
- HR incr.
- hypersensitivity reaction
Safety/Monitoring .
Monitoring Parameters
BP, HR at baseline, then periodically
Pregnancy/Lactation .
Pregnancy
Clinical Summary
weigh risk/benefit during pregnancy; inadequate human data available; possible risk of fetal harm, including decr. fetal wt, fetal death, and teratogenicity based on animal data at >4x MRHD
Pregnancy Registry
encourage patients to enroll in Sunosi Pregnancy Registry at 1-877-283-6220 or at www.sunosipregnancyregistry.com
Lactation
Clinical Summary
weigh risk/benefit while breastfeeding; no human data available to assess risk of infant harm, though drug excreted into milk; no human data available to assess effects on milk production
Pharmacology .
Metabolism: for solriamfetol: unknown; CYP450: none
Excretion: for solriamfetol: urine (95% unchanged); Half-life: 7.1h
Subclass: Narcolepsy/Somnolence ; Sleep-related Breathing Disorders
Mechanism of Action
for solriamfetol: exact mechanism of action unknown; inhibits dopamine and norepinephrine reuptake
Formulary .
No Formulary Selected
Manufacturer/Pricing .
Manufacturer: Axsome Therapeutics, Inc.
DEA/FDA: Schedule IV
Retail Price
Estimated prices only. For current pricing, visit GoodRx.
oral tablet:
- 75 mg (30 ea): $723.00
- 150 mg (30 ea): $723.00
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.